Skip to content

By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Discover updates to RELiZORB and what they may mean for you #

#

Wherever you are in your journey, RELiZORB helps you make the most of your nutritional intake by providing better fat absorption with every tube feed


RELiZORB is the only product designed to break down fats in enteral formula

Your doctor may prescribe RELiZORB for you if your body needs help breaking down (digesting) fats from your enteral tube-feeding formula. RELiZORB is a digestive enzyme cartridge that contains small white beads called iLipase®, which have the digestive enzyme lipase attached to their surface. Lipase is the enzyme that is normally made in the body to break down fats (triglycerides) into absorbable forms (fatty acids and monoglycerides).

The iLipase in RELiZORB is visible through the side of the cartridge and is retained in the cartridge by 2 filters as formula passes through. iLipase beads always remain inside the cartridge and are not ingested.

iLipase®

The digestive enzyme lipase is attached to small white beads that are stored within the RELiZORB cartridge without being ingested.

The digestive enzyme lipase is attached to small white beads that are stored within the RELiZORB cartridge without being ingested

RELiZORB connects directly to your feeding tube

RELiZORB connects directly to your feeding tube
Inside the RELiZORB cartridge is a digestive enzyme called lipase, which is attached to the small white beads that you can see through the clear cartridge.
As the enteral formula passes through the RELiZORB cartridge, it makes contact with the lipase-enzyme bead combination (called iLipase), and the fat in the formula is broken down into absorbable forms (called fatty acids and monoglycerides).
Fats in their absorbable forms (fatty acids and monoglycerides) leave the RELiZORB cartridge and enter your body while the iLipase remains in the cartridge.

#

Get more from your enteral formula

  • RELiZORB is proven to break down fats* during tube feeding
  • RELiZORB can help increase your levels of important omega-3 fatty acids
  • RELiZORB can help reduce the amount of time you experience bothersome gastrointestinal symptoms like diarrhea

Click to see a list of RELiZORB-compatible formulas and pumps.

*Please see list of compatible formulas and hydrolysis information.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral formula or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, enteral formula leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral formulas compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of formulas, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Do not use excessive force when using RELiZORB with enteral syringe push feeding methods.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding.
  • Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.